Generic Medicine Info
Indications and Dosage
Nausea and vomiting
Adult: As hydrochloride: 50 mg up to tid, up to 200 mg/day. For prevention of motion sickness, 1st dose should be given 30 min before travelling.
Child: 6-12 yr: As hydrochloride: 25 mg up to tid. For prevention of motion sickness, 1st dose should be given 30 min before travelling.

Prophylaxis of postoperative nausea and vomiting
Adult: As cyclizine lactate: 50 mg up to tid via slow IV inj over 20 minutes. May give 1st dose 20 minutes before anticipated end of surgery. Treatment should start within the the 1st 24 hours of surgery and should not continue beyond 48 hours.
Renal Impairment
Dose reductions may be needed.
Hepatic Impairment
Avoid in severe liver disease.
Cyclizine lactate may be incompatible with oxytetracycline hydrochloride, chlortetracycline hydrochloride, benzylpenicillin and solutions with a pH ≥6.8.
Premature or full-term neonates.
Special Precautions
Angle closure glaucoma; urinary retention; prostatic hypertrophy; pyloroduodenal obstruction; epilepsy, severe CV disorders; known or suspected QT interval prolongation; hypokalaemia or other electrolyte imbalances; asthma; hepatic impairment. May impair ability to drive or operate machinery. Tolerance with prolonged use. Broken or eczematous skin (topical use). Pregnancy and lactation. Elderly. Children <6 yr. Dependence.
Adverse Reactions
CNS depression e.g. drowsiness to deep sleep, lassitude, dizziness and incoordination. Headache, psychomotor impairment, dry mouth, thickening of mucous secretions, blurred vision, difficult or painful urination, constipation and increased gastric reflux. Occasionally, GI disturbances, palpitations and arrhythmias. Rashes and hypersensitivity reactions. Blood dyscrasias (rare). Convulsions, sweating, myalgia, paraesthesias, extrapyramidal effects, tremor, sleep disturbances, tinnitus, hypotension and hair loss.
Dry mouth, blurred vision, tachycardia, urinary retention, drowsiness, dizziness, inco-ordination, ataxia, weakness, hyperexcitability, disorientation, impaired judgement, hallucinations, hyperkinesia, extrapyramidal motor disturbances, convulsions, hyperpyrexia and respiratory depression. Gastric lavage followed by supportive measures for respiration and circulation.
Drug Interactions
Enhanced sedative effects of alcohol, barbiturates, hypnotics, opioid analgesics, anxiolytic sedatives, antipsychotics. Additive antimuscarinic actions with other antimuscarinic drugs and some antidepressants (TCAs and MAOIs). May mask ototoxicity symptoms caused by aminoglycoside antibiotics.
Description: Cyclizine is a sedative antihistamine with antimuscarinic activity.
Onset: Within 2 hr upon GI absorption.
Duration: Approximately 4 hr.
Absorption: Absorbed from the GI tract.
Metabolism: Hepatically metabolised to relatively inactive metabolite.
Excretion: Plasma elimination half-lives of 20 hr.
MIMS Class
Antivertigo Drugs
Disclaimer: This information is independently developed by MIMS based on Cyclizine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in